Skip to main
  1. Stocks
  2. Intensity Therapeutics Inc
  3. Forecast
INTS

INTS Stock Forecast & Price Target

INTS Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Intensity Therapeutics is viewed favorably because its lead intratumoral candidate INT230-6 is advancing in two key studies, with INVINCIBLE-3 restarting enrollment in 2026 and INVINCIBLE-4 showing early encouraging signals in early-stage, operable TNBC. The first 14 patients showed a 71% pCR rate in Cohort A versus 42% in Cohort B, plus a 44% reduction in grade 3 adverse events and fewer immune-related adverse events, supporting both efficacy and tolerability. Although 3Q26 brought a net loss of $3.5 million on $2.4 million of R&D and $1.2 million of G&A, the company still has clinical momentum and enough progress to justify a positive fundamental outlook despite dilution concerns.

Bears say

Intensity Therapeutics is a late-stage clinical biotechnology company whose outlook is pressured by substantial regulatory risk, including FDA and international agency scrutiny, as well as the possibility that standard-setting organizations could slow or complicate development and commercialization. Its reliance on a single intratumoral platform and product candidate, INT230-6, also heightens execution risk, because any setback in clinical validation, manufacturing, or adoption could materially weaken the investment case. Fundamentally, the company’s lack of profitability and liquidity issues are especially concerning for a biotech with no stated commercial base, while larger competitors may have greater resources to advance similar oncology approaches more quickly.

INTS has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Intensity Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

INTS Analyst Forecast & Price Prediction

Get the latest INTS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in INTS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Intensity Therapeutics Inc (INTS) Forecast

Analysts have given INTS a Buy based on their latest research and market trends.

According to 2 analysts, INTS has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Intensity Therapeutics Inc (INTS)


INTS Analyst Forecast & Price Prediction

Get the latest INTS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in INTS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover INTS stock data and trends